[ Home ] [ Controlled Substances ] [ Stimulants ]
NEA
|
Etilamfetamine (Apetinil) is a stimulant drug of amphetamine chemical class. It is an N-substituted amphetamine with an ethyl group on the amphetamine backbone. It was used as an anorectic or appetite suppressant. Etilamfetamine is a psychoactive drug, which can be used as a recreational drug. Etilamfetamine has been abused as a "designer drug" alternative to amphetamine and possibly methamphetamine. It is a dopamine releasing agent.
Etilamfetamine (Apetinil):
https://drugs.ncats.io/drug/022YON1XMX


https://www.caymanchem.com/msdss/11557m.pdf
It was invented in the early 20th century and was subsequently used as an anorectic or appetite suppressant in the 1950s, but was not as commonly used as other amphetamines. was largely discontinued once newer drugs such as phenmetrazine were introduced. It most likely acts primarily as a dopamine releasing agent. Its activity as a norepinephrine or serotonin releasing agent is not known. Ethylamphetamine can be used as a recreational drug and, while its prevalence is less than amphetamine's, it is still encountered as a substance taken for recreational purposes. Ethylamphetamine produces effects similar to amphetamine and methamphetamine, though its potency is less. At equipotent dosage, ethylamphetamine is subjectively less euphorigenic.
Abcuro secures $200m as it eyes approval for rare muscle disease drug - The funding round, led by New Enterprise Associates (NEA), will be used to complete the Phase II/III ... There are currently no US Food and Drug Administration (FDA)-approved treatments specifically ... Wednesday February 12, 2025 - msn.com Abcuro raises $200m to take muscle disease drug to market - US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of lead drug ulviprubart and file it for approval for inclusion body myositis ... Orbis fundraise shows growing interest in macrocyclic drugs - The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment by a long stretch. That honor belonged to the whopping $410 million netted ... Anterior Secures $20M from NEA to Accelerate AI-Powered Health Insurance Approvals - The investment round was led by NEA, a major player in venture capital ... and Xaira, an AI-based drug discovery startup. His expertise and successful track record in healthcare investments ... Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles - The funds will support the development of Orbis’ pipeline of next-generation oral macrocycle drugs, called ‘ n Cycles.’ This financing was led by NEA (New Enterprise Associates) with ...
| ||
Stimulants | Link to this page |